Persyst 14 EEG Review and Analysis Software

by Persyst Development Corporation  · Based in United States → — Advanced EEG Review and Analysis with AI-Powered Detection.
Critical Care Neurology
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

Persyst 14 EEG Review and Analysis Software is designed to provide comprehensive tools for the review, monitoring, and analysis of electroencephalogram (EEG) recordings. Utilizing the latest deep learning artificial intelligence technology, Persyst 14 introduces a new Seizure Detector that is significantly more accurate and has lower latency than previous versions, achieving higher sensitivity with fewer false positives.

The software seamlessly integrates with major EEG acquisition and review platforms from manufacturers like Natus, Nihon Kohden, Cadwell, Compumedics, and MicroMed. It offers continuous monitoring capabilities, providing time-synchronized, continuous trending of EEG and physiological data, along with online spike and seizure detection.

Key features include continuous Artifact Reduction technology to detect and reduce EMG, eye movement, and electrode artifacts, making EEG easier to read and fundamental for accurate detection and trending. Persyst 14 also provides advanced Spike Detection and Review capabilities, which have been determined to be non-inferior to skilled human readers in recent studies. Additionally, it introduces heart rate trends based on ECG signals, comparison to baseline trends measured in Z-Scores, and the ability to trend other physiological parameters such as ICP, BP, CPP, O2 Sat, and Temperature.

Persyst 14 is widely adopted, with 97 out of 100 of the top hospitals for Neurology in the U.S. using Persyst for EEG monitoring and review, underscoring its role as a standard of care.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered Seizure Detector (deep learning, 10x fewer false positives, lower latency)
  • Advanced Spike Detector and Spike Review (non-inferior to human readers)
  • Continuous Artifact Reduction (EMG, eye movements, electrode artifact)
  • Heart Rate Trend based on ECG signal
  • Comparison to Baseline Trend (Z-Scores)
  • Physiological Trends (ICP, BP, CPP, O2 Sat, Temperature)
  • Rhythmicity Spectrograms
  • Comprehensive qEEG Trends (FFT, Asymmetry, Amplitude integrated EEG, Suppression ratio, Alpha/Delta)
  • Multi-record capability for reviewing multiple recordings as a single study
  • Data API for access to record information, annotations, and raw/artifact-reduced data

Use Cases

  • EEG monitoring and review in top hospitals
  • Epilepsy Monitoring Units (EMU)
  • Neurocritical Care ICU environments
  • Assessment of non-convulsive seizures and other clinically important EEG changes
  • Aid neurologists in the assessment and interpretation of EEG traces
  • Research applications, including iEEG study export with MNI space electrode coordinates

What Physicians Need to Know

EEG Interpretation AI
Persyst 14 utilizes deep learning artificial intelligence for its Seizure Detector, achieving accuracy comparable to expert human readers. It also features an advanced Spike Detector, retrained with additional EEG data to increase sensitivity and decrease false positives, performing within the same range as human experts. The software includes a 'Versus Baseline Trend' that quantifies changes in EEG over time using Z-Scores, aiding in the recognition of subtle, progressive changes.
Seizure Detection
The P14 Seizure Detector is a significant advancement, offering more than ten times the accuracy and over two times lower latency for notifications compared to previous Persyst detectors. It incorporates deep learning AI and allows for patient-specific sensitivity and duration settings, which are carried across recordings. The system features a 'Seizure Probability Trend' to display potential detections. Studies have shown the Persyst 14 algorithm to be statistically noninferior to human experts in seizure detection.
Mobile Notification System
Persyst Mobile App provides timely notifications to users on iOS and Android devices when comments matching a configured filter are added to the patient record. This system facilitates remote access to EEG data, trends, and video, enabling clinicians to receive alerts and review patient information from anywhere, enhancing monitoring and workflow efficiency. It integrates with existing hospital authentication and security infrastructure, ensuring secure, end-to-end encrypted access.
Triage Prioritization Speed
While not a direct 'triage prioritization speed' metric, Persyst 14's significantly lower latency in seizure detection (notifications raised more than a factor of two earlier) and the mobile notification system contribute to faster recognition of critical events. This enables quicker clinical decision-making and potentially faster intervention, aiding in the prioritization of patient care.
Physician Tip

Leverage Persyst 14's advanced AI-driven seizure and spike detection for enhanced accuracy and earlier event recognition, customizing sensitivity settings for individual patient needs. Utilize the 'Versus Baseline Trend' to monitor subtle, long-term EEG changes, particularly valuable in ICU settings or for post-stroke surveillance. Integrate the mobile notification system for remote monitoring and timely alerts, improving patient safety and workflow efficiency. Take advantage of the seamless integration with major EEG acquisition platforms to streamline your workflow and review data from various sources.

Persyst 14 is designed for seamless integration with major EEG acquisition and review platforms, including Natus, Nihon Kohden, Cadwell, Compumedics, and Micromed. It automatically processes EEG records during acquisition, displaying detections and trends in parallel with EEG waveforms. The software functions as a universal reader, supporting nearly 70 different EEG data formats. Persyst Mobile integrates with existing hospital security infrastructure and supports all major EEG manufacturers for secure remote access.

Details

Category Neurology AI
Pricing Contact for pricing
DeploymentOn-premise (Windows 10 Pro recommended), integrates with major EEG acquisition systems.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Persyst 14 EEG Review and Analysis Software received FDA 510(k) clearance (K182181) on November 29, 2018. It is intended for the review, monitoring, and analysis of EEG recordings from scalp electrodes to aid neurologists in EEG assessment, including seizure and spike detection for adult and pediatric patients (spike detection for patients at least one month old, seizure detection for adults ≥18 years old).
Integrations
EHR Not specified
Specialties Critical Care, Neurology

What the Web Says

Persyst 14 EEG Review and Analysis Software is generally well-regarded by physicians for its comprehensive features in seizure detection and trend analysis. It is praised for its user-friendly interface and robust capabilities, though some users note a learning curve and occasional performance issues.

Overall: Positive

Strengths

  • Advanced seizure detection and quantification
  • Comprehensive trend analysis (e.g., Persyst Trend, DSA)
  • User-friendly interface for reviewing long-term EEG
  • Integration with various EEG systems
  • Customizable display and analysis parameters
  • Remote access and review capabilities

Limitations

  • Can be resource-intensive, requiring powerful hardware
  • Steep learning curve for new users to master all features
  • Occasional software glitches or crashes reported
  • Cost can be a barrier for smaller practices or hospitals
  • Some users desire more intuitive report generation
  • Limited Mac OS compatibility

Based on reviews from: Persyst.com (product information), Physician forums and discussions (e.g., Doximity, specialized neurology groups), Healthcare IT reviews (e.g., KLAS Research, vendor comparisons), Reddit (neurology and healthcare technology subreddits), G2 (user reviews), Capterra (user reviews)

Last updated: 2026-07-19

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Persyst 14 EEG Review and Analysis Software

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

FDA
K182181 - 510(k) Premarket Notification - Persyst 14 EEG Review and Analysis Software
This FDA document details the 510(k) premarket notification for Persyst 14 EEG Review and Analysis Software, outlining its intended use for review, monitoring, and analysis of EEG recordings to aid neurologists. It specifies the device's capabilities, such as seizure detection, spike detection, and quantitative EEG measures, and clarifies its limitations and warnings.
2018-11
Persyst Development Corporation
Persyst 14 EEG Review and Analysis Software
Persyst 14 EEG Review and Analysis Software offers a comprehensive suite of tools for Computer Assisted Review of EEG (C.A.R.E.), aiming for accurate, efficient, and rapid analysis of EEG data. The software includes features for seizure detection, spike detection, trends, and artifact reduction.
unknown
Authorea
Innovative Approaches to Training in Evidence-Based Neurology - Authorea
This article discusses innovative approaches to neurology training, including the integration of AI-based devices. Persyst 14 EEG Review and Analysis Software is mentioned as an FDA-approved computerized AI-based device for detecting events by utilizing EEG data to assess the probability of a brain seizure.
2024-09
FDA
K241390 - LVIS Corporation - NeuroMatch 510(k) Premarket Notification
This FDA document references Persyst 14 EEG Review and Analysis Software as a predicate device for LVIS NeuroMatch, a cloud-based software as a medical device for reviewing, monitoring, displaying, and analyzing EEG data. It highlights the similar intended use and classification between the two devices.
2024-11
FDA
K233519 - Epitel, Inc. - REMI-AI Discrete Detection Module (DDM) 510(k) Summary
This FDA 510(k) summary for Epitel's REMI-AI Discrete Detection Module (DDM) identifies Persyst 14 EEG Review and Analysis Software as the predicate device. It states that REMI-AI DDM has the same intended use and similar indications for use, incorporating the same fundamental technology.
2024-01

Videos

Product demos, reviews, and walkthroughs for Persyst 14 EEG Review and Analysis Software.

View all on YouTube

Frequently Asked Questions

Persyst 14 incorporates deep learning AI for advanced seizure and spike detection, significantly improving accuracy and reducing latency compared to previous versions. It also uses AI for continuous artifact reduction, making EEG interpretation easier by minimizing noise from EMG, eye movements, and electrodes.
Persyst 14 is FDA cleared and designed to operate within a hospital's secure environment, not collecting or transmitting Protected Health Information (PHI) externally for clinical use. Optional cloud services for EEG Electrical Source Imaging (ESI) anonymize data before upload, ensuring no PHI leaves the local network.
While highly accurate, Persyst 14's AI detections are not a substitute for real-time human monitoring and can generate false positives, particularly with rhythmic artifacts. Physicians must always interpret AI findings in conjunction with the original EEG waveforms and clinical judgment.
Several other software solutions offer robust EEG analysis, including BESA, encevis, EEGLAB (MATLAB-based), and MNE-Python. These alternatives provide various features like source localization, advanced signal processing, and different visualization tools, catering to diverse clinical and research needs.
Persyst offers various licensing options, including a 'Persyst Prime' subscription model which provides continuous updates, access to new features, priority support, and flexible licensing. Specific pricing details often involve multi-year contracts and volume discounts, and may vary by vendor.
Studies have shown that the Persyst 14 seizure detection algorithm achieved near expert-level accuracy, demonstrating statistical noninferiority compared to human experts in detecting seizures in prolonged EEG recordings. It offers significantly higher sensitivity and lower false-positive rates than previous versions.
Persyst 14 is designed for seamless integration with most major EEG acquisition systems, allowing analysis to begin automatically with acquisition and displaying detections and trends in parallel with waveforms. It also supports remote monitoring via Persyst Mobile, a HIPAA-compliant web-based solution.
Yes, Persyst 14 includes a new AI-based neonatal seizure detector, trained on a large dataset of expert-reviewed neonatal records. This detector identifies seizures in neonates with accuracy comparable to expert human readers and is FDA cleared for this specific use.

Related Tools

Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
CoLumbo C-Spine
Smart Soft Healthcare AD
Clinical Decision Support & Reference
CoLumbo C-Spine is an AI-powered software that processes and analyzes cervical spine MRI exams, assisting clinicians in diagnosis and assessment.
MeRT System
Wave Neuroscience
Mental & Behavioral Health AI
MeRT (Magnetic e-Resonance Therapy) is an advanced, personalized form of TMS that uses your own brainwave data to guide treatment. It's a non-invasive, drug-free option designed to help the brain communicate more efficiently so symptoms of conditions like depression, anxiety, PTSD, TBI, autism, and more can improve.
Paid
Brainomix 360 Hyperdensity
Brainomix Limited
Neurology AI
Brainomix 360 Hyperdensity is an AI-powered neuroimaging software tool that detects and quantifies brain hyperdensities on CT scans, forming a crucial part of the Brainomix 360 Stroke platform for rapid and accurate stroke assessment.
SOMNUM
HoneyNaps
Clinical Decision Support & Reference
SOMNUM is an AI-enabled medical software tool by Honeynaps Co., Ltd. that provides comprehensive sleep analysis to aid in the diagnosis and management of sleep disorders.
DETECT-ME/CFS project
DETECT-ME/CFS project (ME/CFS Research Foundation)
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

See all Neurology AI tools →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.